Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2007

View Archived Issues

KRAS mutation predicts response to panitumumab in colorectal cancer

Polyunsaturated fatty acid erythrocyte content, biomarker of colorectal cancer risk

Paliperidone ER improves sleep in patients with schizophrenia

AEGR-733 lowers LDL-cholesterol, body weight in hypercholesterolemic patients

Pooled DUET results show TMC-125 well tolerated in HIV-infected patients

Caspofungin effective in pediatric patients with fungal infections

Reduced levels of the mGlu3 receptor in the prefrontal cortex of schizophrenic patients

Anesiva reports on clinical plans for Adlea

Pharmion and MethylGene evaluate MGCD-0103 and Taxotere combination for solid tumors

C-Path and Ventana collaborate on targeted therapy initiative with FDA and NCI

Recent patents describe new antidiabetic agents

Positive phase II results reported for dry eye treatment ALTY-0501

Proteolix initiates carfilzomib study in relapsed solid tumors patients

Salvat completes enrollment in phase II SVT-40776 trial

NIH to sponsor preclinical DT-22669 diabetes study

Amarin initiates cardiovascular development strategy

Ark spins out eye-related discoveries to Eyecopharm

Drinkable typhoid vaccine candidate achieves phase II endpoints

Enrollment completed in phase I trial of Lenocta

Sontra Medical Corporation changes to Echo Therapeutics

FDA advisory committee recommends approval for Medtronic's drug-eluting stent

European health authorities accept marketing authorization application for alitretinoin

Novel treatment options for obesity and other metabolic disorders described in recent patents

Novel therapeutic agents for infectious diseases disclosed in recent patent literature

A farnesoid X receptor agonist for the treatment of dyslipidemia

FDA approves Isentress tablets for combination treatment of HIV-1

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Viva in vivo! At EHA, in vivo CAR T data continues to impress
BioWorld
Treatment with first-generation CAR T cells regularly sent patients to the intensive care unit. Now, investigators are envisioning a future where CAR T treatment...